^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Olita (olmutinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

    Excerpt:
    ...- Centrally confirmed T790M mutation positive tumor status from a tumor sample taken after confirmation of disease progression on the most recent anticancer treatment regimen...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

    Excerpt:
    ...- Centrally confirmed T790M mutation positive tumor status from a tumor sample taken after confirmation of disease progression on the most recent anticancer treatment regimen....
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    ELUXA 2: A study that compares a new substance (BI 1482694) with standard chemotherapy in patients who have a particular type of lung cancer (NSCLC with T790 mutation). Only patients who have already taken another anti-cancer drug (EGFR-TKI) and whose tumor has started growing again despite this treatment can participate. ELUXA 2: El estudio compara un nuevo producto (BI 1482694) frente a quimioterapia estándar en pacientes con un tipo particular de cancer de pulmón (CPNM con mutación T790). Sólo aquellos pacientes que hayan tomado una terapia previa para el cancer (EGFR-TKI) y cuyo tumor haya comenzado a crecer a pesar de dicho tratamiento, pueden participar.

    Excerpt:
    ...Presence of T790M mutation confirmed by central laboratory analysis of tumor tissue obtained after disease progression on, or after first-line treatment with an approved EGFR-TKI.5. ...
    Trial ID:
    2015-005079-26
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

    Excerpt:
    ...Confirmation that the extracellular vesicles (EV) extracted from bronchoalveolar lavage fluid (BALF) harbour T790M mutation (It can be replaced previous the same result throughout the follow up period before enrollment.) 9....
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

    Published date:
    01/12/2021
    Excerpt:
    Olmutinib has meaningful clinical activity and a manageable safety profile in patients with T790M-positive non-small cell lung cancer…
    DOI:
    10.1002/cncr.33385